SIGA Technologies Inc
NASDAQ:SIGA

Watchlist Manager
SIGA Technologies Inc Logo
SIGA Technologies Inc
NASDAQ:SIGA
Watchlist
Price: 5.91 USD -1.99% Market Closed
Market Cap: 421.8m USD
Have any thoughts about
SIGA Technologies Inc?
Write Note

SIGA Technologies Inc
Net Issuance of Common Stock

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

SIGA Technologies Inc
Net Issuance of Common Stock Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Issuance of Common Stock CAGR 3Y CAGR 5Y CAGR 10Y
SIGA Technologies Inc
NASDAQ:SIGA
Net Issuance of Common Stock
-$2.5k
CAGR 3-Years
95%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Johnson & Johnson
NYSE:JNJ
Net Issuance of Common Stock
-$1.5B
CAGR 3-Years
6%
CAGR 5-Years
31%
CAGR 10-Years
7%
Bristol-Myers Squibb Co
NYSE:BMY
Net Issuance of Common Stock
$0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Pfizer Inc
NYSE:PFE
Net Issuance of Common Stock
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Merck & Co Inc
NYSE:MRK
Net Issuance of Common Stock
-$1B
CAGR 3-Years
-12%
CAGR 5-Years
35%
CAGR 10-Years
14%
Eli Lilly and Co
NYSE:LLY
Net Issuance of Common Stock
-$446.1m
CAGR 3-Years
4%
CAGR 5-Years
39%
CAGR 10-Years
8%
No Stocks Found

SIGA Technologies Inc
Glance View

Market Cap
421.8m USD
Industry
Pharmaceuticals

SIGA Technologies, Inc. is a commercial-stage pharmaceutical company, which engages in the development and commercialization of solutions for serious unmet medical needs and biothreats. The company is headquartered in New York City, New York and currently employs 39 full-time employees. The Company’s lead product, TPOXX (oral TPOXX), is an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. The firm does not have a manufacturing infrastructure and does not intend to develop one for the manufacture of TPOXX. The company uses contract manufacturing organizations (CMOs) to procure commercial raw materials and supplies, and to manufacture TPOXX. The Company’s CMOs apply methods and controls in facilities, which are uses for manufacturing, processing, packaging, testing, analyzing and holding pharmaceuticals, which conform to current good manufacturing practices (cGMP), the standard set by the FDA for manufacture and storage of pharmaceuticals intended for human use. For the manufacture of oral TPOXX, the Company uses the four CMOs, namely W.R. Grace and Company; Powdersize, LLC; Catalent Pharma Solutions LLC, and Packaging Coordinators, LLC.

SIGA Intrinsic Value
13.95 USD
Undervaluation 58%
Intrinsic Value
Price

See Also

What is SIGA Technologies Inc's Net Issuance of Common Stock?
Net Issuance of Common Stock
-2.5k USD

Based on the financial report for Sep 30, 2024, SIGA Technologies Inc's Net Issuance of Common Stock amounts to -2.5k USD.

What is SIGA Technologies Inc's Net Issuance of Common Stock growth rate?
Net Issuance of Common Stock CAGR 3Y
95%

Over the last year, the Net Issuance of Common Stock growth was 100%. The average annual Net Issuance of Common Stock growth rates for SIGA Technologies Inc have been 95% over the past three years .

Back to Top